Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment

NCT00606502 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

201

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Pralatrexate
DRUG: Erlotinib
DIETARY_SUPPLEMENT: Vitamin B12
DIETARY_SUPPLEMENT: Folic Acid

Sponsor

Spectrum Pharmaceuticals, Inc